title: Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
authors.affiliation: Kronhusgatan 11, 411 05 Gothenburg, Sweden. office@eas-society.org
authors.forename: Jane
authors.initials: J
authors.lastname: Stock
mesh_terms: D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood* / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood*; D002986:Clinical Trials as Topic; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics; D019317:Evidence-Based Medicine; D020022:Genetic Predisposition to Disease; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D017270:Lipoprotein(a) / Q000097:blood* / Q000235:genetics; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood*
chemical_list: D015415:Biomarkers; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D017270:Lipoprotein(a); D014280:Triglycerides